ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0043 • ACR Convergence 2025

    Single-cell and Spatial Transcriptomic Profiling of Muscle Reveals Inflammatory Mechanisms in Anti-glycyl tRNA Synthetase Syndrome

    Takuya Harada1, Hiroyuki Yamashita1, Ami Isoda1, Ken Kawaue1, Mayuko Hayashi1, Yutaro Misawa1, Aruto Yamamoto1, Miyu Wakatsuki1, Yuya Akiyama1, Setsuko Oyama1, Kyoko Motomura1, Hiroyuki Takahashi1, Akiko Mitsuo2, Yuichi Goto3, Eisei Noiri3 and Hiroshi Kaneko1, 1Division of Rheumatic Diseases, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan, 2Division of Clinical Laboratory Medicine, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan, 3National Center Biobank Network, Tokyo, Japan

    Background/Purpose: We characterized the spatial distribution of immune cells and identified hub genes within activated molecular networks in key immune cell populations, based on the…
  • Abstract Number: 0121 • ACR Convergence 2025

    The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry

    Emre Sahin1, Yu (Ray) Zuo2, Danieli Andrade3, Maria Tektonidou4, Vittorio Pengo5, Massimo Radin6, Chary López pedrera7, Diana Paredes-Ruiz8, H Michael Belmont9, Paul Fortin10, Denis WAHL11, Ware Branch12, Maria Gerosa13, Guilherme Ramires de Jesus14, Tatsuya Atsumi15, Maria Efthymiou16, Angela Tincani17, Esther Rodriguez-Almaraz18, Michelle Petri19, Ricard Cervera20, Rohan Willis21, Katrien Devreese22, Maria Laura Bertolaccini23, Hannah Cohen24, Jason S. Knight2 and Doruk Erkan1, 1Hospital for Special Surgery, New York, NY, 2University of Michigan, Ann Arbor, MI, 3University of Sao Paulo, São Paulo, São Paulo, Brazil, 4National and Kapodistrian University of Athens, Athens, Greece, 5Padova University Hospital, Padova, Italy, 6University of Turin, Turin, Turin, Italy, 7Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 8Biobizkaia Health Research Institute, Barakaldo, Spain, 9NYU School of Medicine, New York, NY, 10Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 11University of Lorraine, Nancy, France, 12University of Utah Health Sciences Center, Salt Lake City, UT, 13University of Milan, Milano, Italy, 14Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil, 15Hokkaido University, Sapporo, Japan, 16University College London, London, United Kingdom, 17ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, 18Hospital Universitario 12 de Octubre, Madrid, Spain, 19Johns Hopkins University School of Medicine, Timonium, MD, 20Hospital Clinic Barcelona, Barcelona, Spain, 21University of Texas Medical Branch, Galveston, TX, 22Ghent University, Gent, Belgium, 23King's College London, London, United Kingdom, 24University College London Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: The 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria (CC) focus on IgG and IgM anticardiolipin (aCL) and anti-β2-glycoprotein-I antibodies (aβ2GPI). IgA isotypes were excluded…
  • Abstract Number: 0140 • ACR Convergence 2025

    Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study

    Sindhuja Rajendran1, ashish mathew2, sukesh chandran nair3, john mathew2 and ruchika goel2, 1Christian Medical College ,Vellore, Madurai, Tamil Nadu, India, 2Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, 3Christian,Medical College ,Vellore ,India, Vellore, Tamil Nadu, India

    Background/Purpose: Non-criteria manifestations occur in 24% in Primary antiphospholipid syndrome (PAPS) . The efficacy of immunosuppressants in patients with above condition is not certain due…
  • Abstract Number: 0101 • ACR Convergence 2025

    Enrichment of putative bacteria-reactive gut-derived IL-17+ tissue resident memory helper T cells in arthritic ankles in the SKG mouse model of spondyloarthritis

    Benjamin Cai1, Megan Soon2, Zewen Kelvin Tuong2, Mark Morrison2, Anne-Sophie Bergot3 and Ranjeny Thomas4, 1Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia, 2Frazer Institute, The University of Queensland, Brisbane, Australia, 3Frazer Institute, The University of Queensland, Woolloongabba, Queensland, Australia, 4Frazer Institute, University of Queensland, Brisbane, Queensland, Australia

    Background/Purpose: In spondyloarthropathy (SpA), arthritis is often associated with gut inflammation. The strong genetic association with HLA-B27 implicates involvement of T cells, but how gut…
  • Abstract Number: 0144 • ACR Convergence 2025

    Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey

    Zeynep Belce Erton1, Joann Vega2, Hannah Cohen3 and Doruk Erkan2, 1Hospital for Special Surgery, Brooklyn, NY, 2hospital for special surgery, New York, NY, 3University College London Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: APS ACTION is a multidisciplinary, international research network focused on developing collaborative studies to improve antiphospholipid syndrome (APS) diagnosis and management. There is limited…
  • Abstract Number: 0145 • ACR Convergence 2025

    Population Assessment of Cancer Incidence among Patients with Idiopathic Inflammatory Myopathies in North Carolina

    Astia Allenzara1, Ben Albright2, Xi Zhou2, Amanda Nelson3, Laura Green4, Katherine Reeder-Hayes4, Jennifer Lund4, Caroline Thompson4 and Chris Baggett4, 1UNC, Chapel Hill, NC, 2University of North Carolina, Chapel Hill, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, 4University of North Carolina, Chapel Hill

    Background/Purpose: Cancer is highly prevalent and a leading cause of death for patients with Idiopathic Inflammatory Myopathies (IIM). Evaluating cancer type and stage at diagnosis…
  • Abstract Number: 0039 • ACR Convergence 2025

    Hemophagocytic Lymphohistiocytosis Gene Variants in Severe COVID-19 Cytokine Storm Syndrome

    randy Cron1, Abhishek Kamath1, Mingce Zhang1, Devin Abhser2, Lesley Jackson1 and Walter Winn Chatham3, 1University of Alabama at Birmingham, Birmingham, AL, 2Kaiser Permanente Research Bank, Oakland, CA, 3University of Nevada, Las Vegas, Las Vegas, NV

    Background/Purpose: Severe COVID-19 infection resulting in hospitalization shares features with frequently fatal cytokine storm syndromes (CSS), such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome…
  • Abstract Number: 0110 • ACR Convergence 2025

    SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses

    Yuka Nakao1, Astha Patel1, Bahram Razani2, Steven yu1, Steven Lazarevsky2, Marlys Fassett2 and Judith Ashouri1, 1University of California, San Francisco, San Francisco, CA, 2UCSF Department of Dermatology, San Francisco, CA

    Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are chronic immune-mediated diseases affecting millions, yet early immunologic triggers remain poorly defined. Therapies targeting TNFα, IL-17, and…
  • Abstract Number: 0132 • ACR Convergence 2025

    Increased Expression of Gas6 and Its Tyrosine Kinase Receptor Tyro3 Are Associated with Antiphospholipid Syndrome

    Fanshu Li, Ranran Yao, Fanlei Hu, Liling Xu and Chun Li, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic)

    Background/Purpose: Growth arrest specific protein 6 (Gas6) is a member of the vitamin K-dependent protein family. It participates in apoptosis, inflammatory response and immunomodulation by…
  • Abstract Number: 1064 • ACR Convergence 2025

    Characterization of Juvenile Idiopathic Arthritis in Indigenous North American Children enrolled in a North American registry

    Hayley M Lynch1, Jordan E. Roberts1 and James N. Jarvis2, 1Seattle Children's Hospital/UW, Seattle, WA, 2University of Washington Center for Indigenous Health, Seattle, WA

    Background/Purpose: Several studies detail a higher prevalence and severity of juvenile idiopathic arthritis (JIA) in Indigenous North American (INA) children compared to the general population.…
  • Abstract Number: 0127 • ACR Convergence 2025

    Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease

    Wenying Liang1, Qinmengge Li2, Jacqueline Madison1, Ran Jing1, Emily Chong1, Yiran Shen1, Rachael Bogle3, Srilakshmi Yalavarthi1, Cyrus Sarosh4, Ajay Tambralli1, Yu (Ray) Zuo1, Johann Gudjonsson1, Hui Shi5, Pei-Suen Tsou1, Alex Tsoi3 and Jason S. Knight1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ypsilanti, MI, 3University of Michigan, Holland, OH, 4University of Michigan, Temperance, MI, 5Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)

    Background/Purpose: Some of the rarer manifestations of antiphospholipid syndrome (APS), such as cardiac valve disease, remain poorly understood at the molecular level. A previous study…
  • Abstract Number: 0152 • ACR Convergence 2025

    Exploring internet use and health information behaviour in patients with inflammatory rheumatic musculoskeletal diseases (RMD)

    Ioana Andreica1, Sulafa Chikh Mohamad2, Dieter Wiek3, Birgit Barten3, Iulia Roman4, Anja Kremser5, David Kiefer6, Philipp Sewerin1, Uta Kiltz7 and Xenofon Baraliakos7, 1Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Herne, Germany, 3Deutsche Rheuma Liga, Germany, Bonn, 4Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Herne, Germany, 5Rheumazentrum Ruhrgebiet, Herne, Germany, 6Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, 7Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: Digital health literacy has recently become a focus of patient-centred recommendations, not only as a key social determinant of health, but also as a…
  • Abstract Number: 0048 • ACR Convergence 2025

    Integrative Spatial Proteomics and Single-Cell RNA Sequencing Unveil Molecular Complexity in Rheumatoid Arthritis for Novel Therapeutic Targeting

    Xue Wang1, Fei Wang2, Sílvia Sisó2, Archana Iyer2, Heather Knight2, Lori Duggan2, Yingli Yang2, Liang Jin2, Baoling Cui2, Yupeng He3, Jan Schejbal2, Lucy Phillips2, Bohdan Harvey4 and Yu Tian2, 1AbbVie, South San Francisco, CA, 2AbbVie, Worcester, MA, 3AbbVie, North Chicago, IL, 4AbbVie, Cambridge, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation, fibroblast proliferation and progressive joint damage. Understanding the heterogeneity of RA and…
  • Abstract Number: 0125 • ACR Convergence 2025

    The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases

    Dionysis Nikolopoulos1, Konstantinos Charitidis2, Julius Lindblom2, Maria O Borghi3, Guillermo Barturen4, Marta Alarcon-Riquelme5, Lorenzo Beretta6 and Ioannis Parodis7, 1Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3IRCCS, Istituto Auxologico Italiano, Milan, Italy, 4Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, 5Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 6Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, 7Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden

    Background/Purpose: Primary antiphospholipid syndrome (pAPS) is an autoimmune disease that, unlike many other autoimmune diseases, commonly presents with thrombotic events rather than inflammatory manifestations. A…
  • Abstract Number: 0149 • ACR Convergence 2025

    Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis

    Viengneesee Thao, Molly Moore Jeffery, Nafisseh Warner and Elena myasoedova, Mayo Clinic, Rochester, MN

    Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…
  • « Previous Page
  • 1
  • …
  • 69
  • 70
  • 71
  • 72
  • 73
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology